February 11, 2019 - The Birth Defect Surveillance Group, part of ZikaPLAN’s Work Package 8 (Disease Burden and Risk Assessment), announces the launch of the Global Birth Defects website. Read more
December 19, 2018 - Scientists at the KU Leuven Rega Institute, members of both the ZikaPLAN and ZIKAlliance consortia, have developed a new vaccine against the Zika virus. This vaccine should prevent the virus from causing microcephaly and other serious ... Read more
November 29, 2018 - Diagnosing Zika in the field presents specific challenges as other diseases, such as chikungunya and dengue, present in the same areas, can give a false positive on diagnostic tests. Read more
November 23, 2018 - The mosquito Aedes aegypti should be considered one of the most dangerous animals on the planet. This is because the Aedes aegypti female carries several viruses that can cause diseases such as yellow fever, dengue and ... Read more
September 19, 2018 - On the 11 and 12of September, scientists from leading research organizations across the world met for the ZikaPLAN Consortium meeting at the London School of Hygiene & Tropical Medicine in the UK. Read more
Van den Bossche et al. – European Journal of Clinical Microbiology and Infectious Diseases, January 2019
Diagnosing a patient with Zika infection is not always straightforward. In this article, the authors aim to describe the data collected from December 2015 to December 2017 and discuss the implemented algorithm and diagnostic challenges they encountered.
Defining the spectrum of neurological diseases associated with Zika virus (ZIKV) infection, in both the central nervous system (CNS) and peripheral nervous system (PNS) of adults and children.
To protect pregnant women, novel, wash-in detergent formulations and long-lasting plastic technologies containing repellents for the treatment of clothing and other wearable repellent technologies are being developed using new microencapsulation techniques.
Identifying the major T-cell epitopes and cross reactive B-cell epitopes on ZIKV and assessing the role of flavivirus antibodies in protective and pathogenic immunity following ZIKV through antibody dependent enhancement (ADE).
ZikaPLAN has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 734584.